Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
Biomolecules. 2024 Sep 26;14(10):1215. doi: 10.3390/biom14101215.
Autosomal dominant polycystic kidney disease (ADPKD) is a predominant genetic disease, which is caused by mutations in PKD genes and is associated with DNA damage in cystic cells. The intrinsic stimulator of interferon genes (STING) pathway is crucial for recognizing damaged DNA in the cytosol, triggering the expression of inflammatory cytokines to activate defense mechanisms. However, the precise roles and mechanisms of STING in ADPKD remain elusive. In this study, we show that mutant mouse kidneys show upregulation of STING, which is stimulated by the DNAs of nuclear and mitochondrial origin. The activation of STING promotes cyst growth through increasing (1) the activation of NF-κB in mutant cells and (2) the recruitment of macrophages in the interstitial and peri-cystic regions in mutant mouse kidneys via NF-κB mediating the upregulation of TNF-α and MCP-1. Targeting STING with its specific inhibitor C-176 delays cyst growth in an early-stage aggressive conditional knockout mouse model and a milder long-lasting mutant mouse model. Targeting STING normalizes mitochondrial structure and function, decreases the formation of micronuclei, induces mutant renal epithelial cell death via p53 signaling, and decreases renal fibrosis in mutant mouse kidneys. These results support that STING is a novel therapeutic target for ADPKD treatment.
常染色体显性多囊肾病 (ADPKD) 是一种主要的遗传疾病,由 PKD 基因突变引起,并与囊性细胞中的 DNA 损伤有关。干扰素基因刺激物 (STING) 途径的内在刺激物对于识别细胞质中的受损 DNA 至关重要,它可以触发炎症细胞因子的表达,激活防御机制。然而,STING 在 ADPKD 中的确切作用和机制仍不清楚。在这项研究中,我们表明突变型小鼠肾脏中 STING 的表达上调,这是由核和线粒体来源的 DNA 刺激的。STING 的激活通过增加 (1) 突变细胞中 NF-κB 的激活和 (2) 通过 NF-κB 介导 TNF-α 和 MCP-1 的上调,在 突变型小鼠肾脏的间质和囊周区域募集巨噬细胞,从而促进囊肿生长。用其特异性抑制剂 C-176 靶向 STING 可延迟早期侵袭性 条件性敲除小鼠模型和轻度持续时间较长的 突变型小鼠模型中的囊肿生长。靶向 STING 可使线粒体结构和功能正常化,减少微核的形成,通过 p53 信号诱导 突变型肾上皮细胞死亡,并减少 突变型小鼠肾脏中的肾纤维化。这些结果支持 STING 是 ADPKD 治疗的一个新的治疗靶点。